Health Care M&A Weekly Deals, The Week Ending February 16, 2018

We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report.

This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search.

Biotechnology
AcquirerTargetPrice
Bioverativ Inc.License to lentiviral vectors$5 million
Oncologie, Inc.Exclusive license to lefitolimod$369 million
Lee’s Pharmaceutical LimitedExclusive rights to GCC-4401CN/A
Bristol-Myers Squibb CompanyCollaboration on NKTR-214$1.85 billion
Astellas Pharma, Inc.Universal Cells, Inc.
Kerafast Inc.Absolute Antibody Ltd.Merger
Roivant SciencesLicense agreement to imeglimin$35 million
Seattle Genetics, Inc.License to Anticalin technology$30 million
eHealth
AcquirerTargetPrice
Fitbit, Inc.Twine Health, Inc.N/A
StaywellProvata HealthN/A
Hospitals
AcquirerTargetPrice
Allegiance Health ManagementByrd Regional HospitalN/A
Long-Term Care
AcquirerTargetPrice
Partnership buyerSignature HealthCARE of Pinellas Park$12 million
Regional operatorLegacy Place Portfolio$32.6 million
Private investment groupGrandview Assisted Living$7 million
Medical Devices
AcquirerTargetPrice
LivaNova PLCTandemLife$200,000,000
Physician Medical Groups
AcquirerTargetPrice
Platinum Dermatology PartnersCenter for Dermatology & Plastic SurgeryN/A
Epiphany DermatologyDermatology Associates, Inc.N/A
Other
AcquirerTargetPrice
Charles River Laboratories International, Inc.MPI Research$800 million
CityMDSTAT HealthN/A
Press Ganey AssociatesHealthStream’s patient experience businessN/A
   

 

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *